Cerus Given New $5.00 Price Target at Wedbush (CERS)
Several other analysts have also recently commented on the stock. Analysts at MLV Capital raised their price target on shares of Cerus from $5.00 to $7.50 in a research note to investors on Monday. They now have a buy rating on the stock.
Shares of Cerus traded up 1.32% during mid-day trading on Monday, hitting $4.215. Cerus has a 52 week low of $2.68 and a 52 week high of $4.53. The stock’s 50-day moving average is currently $3.34. The company’s market cap is $234.6 million.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.